Global Crohn's Disease (CD) Market 2015-2019
CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties.
TechNavio's analysts forecast the Global CD market to grow at a CAGR of 2.84 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global CD market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators.
TechNavio's report, the Global CD Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global CD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
TechNavio Announces the Publication of its Research Report – Global CD Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global CD Market: AbbVie Inc., AstraZeneca plc, Biogen Idec Inc., Johnson & Johnson, Takeda Pharmaceutical Co. Ltd. and UCB SA
Other Prominent Vendors in the market are: Amgen, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Merck, Mitsubishi Tanabe, Novartis, Novo Nordisk and Pfizer.
Commenting on the report, an analyst from TechNavio’s team said: “An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market.”
According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually.
Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market.
AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical, UCB, Amgen, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals,Merck, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook